Immutep Limited

Immutep is a clinical-stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease.

The company are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response.

Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders.


Company news

Immutep Limited

Immutep: fighting the good fight

Immutep (ASX: IMM) are global leaders in the understanding and development of  immunotherapy drugs for cancer and autoimmune diseases. IMM's objective is to harness and strengthen the power of the body’s own immune systems through therapeutic intervention for the...

We help investors gain insights into your company through high quality research reports.

We provide a full suite of corporate access services.

Corporate Connect Research

Level 7, 7 Macquarie Place
Sydney NSW 2000

Email us

Contact us

4 + 11 =